TRDA — Entrada Therapeutics Income Statement
0.000.00%
- $481.07m
- $153.65m
- $129.01m
- 61
- 63
- 79
- 76
Annual income statement for Entrada Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 129 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 11.8 | 26.7 | 51.1 | 97.2 | 132 |
Operating Profit | -11.8 | -26.7 | -51.1 | -97.2 | -3.16 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.1 | -26.5 | -51.2 | -94.6 | 12.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.1 | -26.5 | -51.2 | -94.6 | -6.68 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.1 | -26.5 | -51.2 | -94.6 | -6.68 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.1 | -26.5 | -51.2 | -94.6 | -6.68 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.171 | -0.887 | -8.16 | -3.02 | -0.202 |
Dividends per Share |